CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, ...

Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Patients on GLP-1 medications lost about half as much weight as participants did in clinical trials, NYU researchers found.

T he increasing use of GLP-1 medications for weight loss has triggered a corresponding surge in body lift surgeries, as ...

A study presented at the American Society for Metabolic and Bariatric Surgery highlighted that bariatric surgeries, ...

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with ...

Here are eight takeaways from our conversation with Kessler about using the GLP-1 drugs, and the changing landscape of weight loss. Foods high in salt, sugar and fat that are "highly palatable and ...